The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Intra/Extracellular Lactic Acid Exhaustion for Synergistic Metabolic Therapy and Immunotherapy of Tumors
Abstract
Regulating the tumor microenvironment (TME) has been a promising strategy to improve antitumor therapy. Here, a red blood cell membrane (mRBC)‐camouflaged hollow MnO 2 (HMnO 2) catalytic nanosystem embedded with lactate oxidase (LOX) and a glycolysis inhibitor (denoted as PMLR) is constructed for intra/extracellular lactic acid exhaustion as well as synergistic metabolic therapy and immunotherapy of tumor. Benefiting from the long‐circulation property of the mRBC, the nanosystem can gradually accumulate in a tumor site through the enhanced permeability and retention (EPR) effect. The extracellular nanosystem consumes lactic acid in the TME by catalyzing its oxidation reaction via LOX. Meanwhile, the intracellular nanosystem releases the glycolysis inhibitor to cut off the source of lactic acid, as well as achieve antitumor metabolic therapy through the blockade of the adenosine triphosphate (ATP) supply. Both the extracellular and intracellular processes can be sensitized by O 2, which can be produced during the decomposition of endogenous H 2 O 2 catalyzed by the PMLR nanosystem. The results show that the PMLR nanosystem can ceaselessly remove lactic acid, and then lead to an immunocompetent TME. Moreover, this TME regulation strategy can effectively improve the antitumor effect of anti‐PDL1 therapy without the employment of any immune agonists to avoid the autoimmunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Toll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039
Yang, G., Xu, L., Chao, Y., Xu, J., Sun, X., Wu, Y., Peng, R., & Liu, Z. (2017) · Nature Communications · doi:10.1038/s41467-017-01050-0 · Cited by 1,477
Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Duan, X., Chan, C., & Lin, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201804882 · Cited by 1,033
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
Ehrchen, J. M., Sunderkötter, C., Foell, D., Vogl, T., & Roth, J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1008647 · Cited by 846
He, C., Duan, X., Guo, N., Chan, C., Poon, C., Weichselbaum, R. R., & Lin, W. (2016) · Nature Communications · doi:10.1038/ncomms12499 · Cited by 754
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Auslander, N., Zhang, G., Lee, J. S., Frederick, D. T., Miao, B., Moll, T., Tian, T., Wei, Z., Madan, S., Sullivan, R. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0157-9 · Cited by 738
A Strategy for Probing the Function of Noncoding RNAs Finds a Repressor of NFAT
Willingham, A. T., Orth, A. P., Batalov, S., Peters, E. C., Wen, B. G., Aza-Blanc, P., Hogenesch, J. B., & Schultz, P. G. (2005) · Science · doi:10.1126/science.1115901 · Cited by 729
Song, M., Liu, T., Shi, C., Zhang, X., & Chen, X. (2016) · ACS Nano · doi:10.1021/acsnano.5b06779 · Cited by 662
Self-citationZhu, W., Dong, Z., Fu, T., Liu, J., Chen, Q., Li, Y., Zhu, R., Xu, L., & Liu, Z. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201600676 · Cited by 588
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
The microbiome in autoimmune diseases
De Luca, F., & Shoenfeld, Y. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13158 · Cited by 510
Yu, Z., Zhou, P., Pan, W., Li, N., & Tang, B. (2018) · Nature Communications · doi:10.1038/s41467-018-07197-8 · Cited by 494
Cancer and the tumor microenvironment: a review of an essential relationship
Mbeunkui, F., & Johann, D. J. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0881-9 · Cited by 487
Feng, B., Zhou, F., Hou, B., Wang, D., Wang, T., Fu, Y., Ma, Y., Yu, H., & Li, Y. (2018) · Advanced Materials · doi:10.1002/adma.201803001 · Cited by 451
Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2017) · Nature Communications · doi:10.1038/ncomms14754 · Cited by 350
Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement
Liu, J., Chen, Q., Feng, L., & Liu, Z. (2018) · Nano Today · doi:10.1016/j.nantod.2018.06.008 · Cited by 327
Xu, J., Han, W., Yang, P., Jia, T., Dong, S., Bi, H., Gulzar, A., Yang, D., Gai, S., He, F., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201803804 · Cited by 315
Lorenz, P., Roychowdhury, S., Engelmann, M., Wolf, G., & Horn, T. F. W. (2003) · Nitric Oxide · doi:10.1016/j.niox.2003.09.005 · Cited by 297
Webb, A. H., Gao, B. T., Goldsmith, Z. K., Irvine, A. S., Saleh, N., Lee, R. P., Lendermon, J. B., Bheemreddy, R., Zhang, Q., Brennan, R. C., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3418-y · Cited by 275
Tsai, C.-S., Chen, F.-H., Wang, C.-C., Huang, H.-L., Jung, S.-M., Wu, C.-J., Lee, C.-C., McBride, W. H., Chiang, C.-S., & Hong, J.-H. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.01.041 · Cited by 257
Liu, L., Zhang, Y., Qiu, W., Zhang, L., Gao, F., Li, B., Xu, L., Fan, J., Li, Z., & Zhang, X. (2017) · Small · doi:10.1002/smll.201701621 · Cited by 240
Self-citationZhang, X., Xi, Z., Machuki, J. O., Luo, J., Yang, D., Li, J., Cai, W., Yang, Y., Zhang, L., Tian, J., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b09786 · Cited by 233
Self-citationLactate and Immunosuppression in Sepsis
Nolt, B., Tu, F., Wang, X., Ha, T., Winter, R., Williams, D. L., & Li, C. (2018) · Shock · doi:10.1097/shk.0000000000000958 · Cited by 219
Xintaropoulou, C., Ward, C., Wise, A., Marston, H., Turnbull, A., & Langdon, S. P. (2015) · Oncotarget · doi:10.18632/oncotarget.4499 · Cited by 159
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Fan, Q., Chen, Z., Wang, C., & Liu, Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802540 · Cited by 129
Antón, M., Alén, F., de Heras, R. G., Serrano, A., Pavón, F. J., Leza, J. C., García‐Bueno, B., de Fonseca, F. R., & Orío, L. (2016) · Addiction Biology · doi:10.1111/adb.12365 · Cited by 128
Metabolic Stress in the Immune Function of T Cells, Macrophages and Dendritic Cells
Domblides, C., Lartigue, L., & Faustin, B. (2018) · Cells · doi:10.3390/cells7070068 · Cited by 120
Highly Integrated Nano-Platform for Breaking the Barrier between Chemotherapy and Immunotherapy
Zheng, D., Chen, J., Zhu, J., Rong, L., Li, B., Lei, Q., Fan, J., Zou, M., Li, C., Cheng, S., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b01432 · Cited by 117
Self-citationHuang, G., Zhang, K., Chen, S., Li, S.-H., Wang, L., Wang, L., Liu, R., Gao, J., & Yang, H. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00794a · Cited by 105
Shi, P., Qu, K., Wang, J., Li, M. C., Ren, J., & Qu, X. (2012) · Chemical Communications · doi:10.1039/c2cc33543c · Cited by 103
Abumanhal-Masarweh, H., Koren, L., Zinger, A., Yaari, Z. A., Krinsky, N., Kaneti, G., Dahan, N., Lupu-Haber, Y., Suss-Toby, E., Weiss‐Messer, E., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.004 · Cited by 100
Ippolito, J. E., Brandenburg, M. W., Ge, X., Crowley, J. R., Kirmess, K. M., Som, A., d’Avignon, D. A., Arbeit, J. M., Achilefu, S., Yarasheski, K. E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159675 · Cited by 40
Zhang, K., Zhou, J. J., Zhou, H. W., Wu, Y., Liu, R., Wang, L., Lin, W., Huang, G., & Yang, H. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10086 · Cited by 40
Tumors sweeten macrophages with acids
Sekine, H., Yamamoto, M. P., & Motohashi, H. (2018) · Nature Immunology · doi:10.1038/s41590-018-0258-0 · Cited by 36
Mignani, S. M., Rodrigues, J., Roy, R., Shi, X., Ceña, V., Kazzouli, S. E., & Majoral, J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.001 · Cited by 35
He, X., Liu, B., Ai, S., Xu, L., Zhuo, R., & Cheng, S. (2017) · Materials Today Chemistry · doi:10.1016/j.mtchem.2017.01.006 · Cited by 30
Cited by
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
Kumari, N., & Choi, S. H. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02272-x · Cited by 315
Duo, Y., Zhu, D., Sun, X., Suo, M., Zheng, Z., Jiang, W., & Tang, B. Z. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120755 · Cited by 58
Metadata
- Authors
- Gao, F., Tang, Y., Liu, W., Zou, M., Huang, C., Liu, C., & Zhang, X.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2019-11-06
- Volume
- 31
- Issue
- 51
- Pages
- e1904639-e1904639
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2986793362
- Cited by
- 357
- References
- 42
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.